Ignite Creation Date:
2024-05-06 @ 8:25 PM
Last Modification Date:
2024-10-26 @ 3:27 PM
Study NCT ID:
NCT06376773
Status:
COMPLETED
Last Update Posted:
2024-04-19
First Post:
2024-04-15
Brief Title:
Neoadjuvant Treatment Based on Gastric Cancer Molecular Subtyping
Sponsor:
Fujian Medical University
Organization:
Fujian Medical University
Study Overview
Official Title:
Neoadjuvant Treatment Based on Gastric Cancer Molecular Subtyping Chemotherapy Immunotherapy or Targeted Therapy -A Retrospective Real-World Data Analysis
Status:
COMPLETED
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Extensive research employing diverse omics methodologies has unveiled a varied landscape of gastric cancer GC Recent progress in next-generation sequencing and other genomic technologies has facilitated a more intricate exploration of GC at the molecular level This study aimed to identify the most effective drug therapeutics for patients with the mesenchymal subtype of gastric cancerBased on RNA-seq transcriptome 234 patients were divided into four molecular subtypes mesenchymal immunogenic metabolic and classicOur analysis has revealed that for neoadjuvant therapy in advanced gastric cancer AGC the mesenchymal subtype stands out as the ideal patient population benefiting from Apatinib without a concurrent increase in postoperative complications
Detailed Description:
The advent of immunotherapy and targeted therapies has recently provided new options for AGC treatment However not all patients benefit from immunotherapy or targeted therapy resulting in unsatisfactory overall treatment outcomes during the perioperative period An ineffective treatment imposes significant financial burden causes drug-related side effects that deteriorate their quality of life and potentially delays subsequent treatment
Evaluate the objective response rate ORR of the combination of camrelizumb apatinib and neoadjuvant chemotherapy for the treatment of advanced gastric patient Median survival time OS
Disease free survival time DFS
Evaluate the objective response rate ORR of the combination of camrelizumb apatinib and neoadjuvant chemotherapy for the treatment of advanced gastric patient Median survival time OS
Disease free survival time DFS
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None